KV to use Acrux' spray for six new products

KV Pharmaceutical has expanded its collaboration with Australian drug delivery company Acrux. The US drugmaker will incorporate Acrux' unique spray technology for delivering drugs through the skin in up to six additional new branded products to be designated by KV for future development.

The agreement also calls for KV to license to Acrux the regulatory data and US regulatory filings pertaining to KV's recently launched Evamist, the first and only estradiol transdermal spray for moderate-to-severe vasomotor symptoms associated with menopause, so that latter may file a similar product in key international markets.

Upon completion of development and necessary regulatory approvals, the six additional branded products would be launched by KV's Ther-Rx subsidiary for sale in the USA or, for certain products, on a worldwide basis. The agreement also provides a framework for the potential to add further products in the future. Three of these products are in the pre-clinical development stage. KV says the deal is consistent with its goal of expanding Ther-Rx into new therapeutic areas.